Home › Cancro (tutti i tipi) › Oregon › Portland
Studi clinici su Cancro (tutti i tipi) a Portland, OR
34 studi su Cancro (tutti i tipi) cercano partecipanti presso sedi a Portland e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
In reclutamentoFase 2
- Providence Portland Medical Center /ID# 277727, Portland
A Study of ASP3082 in Adults With Advanced Solid Tumors
In reclutamentoFase 1
- Oregon Health and Science University, Portland
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
In reclutamentoFase 1
- Oregon Health & Science University, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
In reclutamentoFase 1
- PHN-012-001 Site, Portland
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
In reclutamentoFase 3
- Investigative Site, Portland
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
In reclutamentoFase 2/3
- OHSU Center for Health & Healing 1, Portland
- Oregon Health and Science University, Portland
- OSHU Center for Health and Healing 2, Portland
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
In reclutamentoFase 3
- Oregon Health and Science University /ID# 280071, Portland
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
In reclutamentoFase 2
- Providence Health & Services, Portland
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
In reclutamentoFase 2/3
- Providence Portland Medical Center, Portland
- Oregon Health and Science University OHSU, Portland
Connect for Cancer Prevention Study (Connect)
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Kaiser Permanente Northwest, Portland
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
In reclutamentoFase 1/2
- Oregon Health and Science University ( Site 3004), Portland
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
In reclutamentoFase 1/2
- Oregon Health and Science University /ID# 272282, Portland
A Phase 1/1b Study of IAM1363 in HER2 Cancers
In reclutamentoFase 1
- Providence Cancer Institute, Portland
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
In reclutamentoFase 3
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
In reclutamentoFase 1
- Providence Portland Medical Center, Portland
IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer
In reclutamentoStudio osservazionale
- Oregon Health and Science University, Portland
Project: Every Child for Younger Patients With Cancer
In reclutamentoStudio osservazionale
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 1/2
- Oregon Health and Science University, Portland
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
In reclutamentoFase 2
- Oregon Health and Science University, Portland
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
In reclutamentoFase 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- e altri 2
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
In reclutamentoFase 2
- OHSU Knight Cancer Institute, Portland
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
In reclutamentoFase 2
- Northwest Cancer Specialists /ID# 275151, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Providence Cancer Institute Franz Clinic, Portland
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
In reclutamentoFase 2
- Oregon Health and Science University, Portland
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
In reclutamentoFase 1
- GSK Investigational Site, Portland
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
In reclutamento
- VA Portland Health Care System, Portland, OR, Portland
Galleri® in the Medicare Population.
In reclutamentoVolontari sani benvenuti
- OHSU CEDAR Clinical Trials Portland, Portland
- OHSU CEDAR Clinical Trials Richmond, Portland
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
In reclutamentoFase 2
- Oregon Health & Science Institute (OHSU), Portland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
In reclutamentoFase 1/2
- Providence Neurological Specialties West, Portland
Beat Childhood Cancer Specimen Banking and Data Registry
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Randall Children's Hospital, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Portland
Observational Study of Iris Tumors
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Oregon Health & Science University, Portland
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
In reclutamentoFase 1/2
- Oregon Health & Science University, Portland
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
In reclutamento
- Kaiser Permanente Northwest - Oncology Clinic, Portland
Studi su Cancro (tutti i tipi) in altre città
- Houston, TX121 studi
- New York City, NY109 studi
- Boston, MA85 studi
- Los Angeles, CA74 studi
- Nashville, TN65 studi
- Philadelphia, PA59 studi
- Washington, DC58 studi
- Durham, NC58 studi
- Chicago, IL51 studi
- Atlanta, GA49 studi
- Seattle, WA49 studi
- Arlington, VA48 studi
Altri studi a Portland
- Cancro del polmone non a piccole cellule46 studi
- Cancro al seno33 studi
- Cancro alla prostata33 studi
- Cancro metastatico29 studi
- Cancro colorettale28 studi
- Cancro ovarico27 studi
- Cancro ai polmoni26 studi
- Leucemia mieloide acuta25 studi
- Cancro dell'endometrio24 studi
- Carcinoma a cellule squamose della testa e del collo19 studi
- Cancro pancreatico19 studi
- Insufficienza cardiaca17 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.